Initial clinical experience of a steerable access device for EUS-guided biliary drainage - 24/12/19
Abstract |
Background and Aims |
EUS-guided biliary drainage (EUS-BD) has been used as a rescue procedure after failed endoscopic retrograde cholangiography (ERC), and there is growing interest in EUS-BD as a primary therapy for distal malignant biliary obstruction. After EUS-guided needle puncture of an obstructed bile duct, directional control of wire advancement remains an area of need, potentially addressed by a new steerable EUS access system. The aim of this study was to evaluate the safety and efficacy of this novel steerable access system in patients undergoing EUS-BD after failed ERC.
Methods |
We performed a retrospective study of prospectively acquired data at 3 tertiary academic hospitals. Consecutive patients who had failed ERC followed by EUS-BD using the access device were included. Primary outcomes were safety and technical feasibility (successful completion of EUS-BD). Secondary outcomes were clinical success (75% improvement in liver function tests at 30 days) and device performance.
Results |
Twenty-two consecutive patients underwent EUS-BD between October 10, 2018 and March 3, 2019. Needle puncture and selective wire advancement in the intended direction were both successful in 100% of cases (22/22). Technical success was 95% (21/22). Fifty-nine percent (13) underwent rendezvous, 32% (7) underwent choledochoduodenostomy, and 4.5% (1) underwent hepaticogastrostomy. One patient (4.5%) underwent percutaneous transhepatic cholangiography. There were no cases of wire shearing. The adverse event rate was 4.5% (mild pancreatitis in 1 patient). There was no bile leak, bleeding, or death at 30 days' follow-up.
Conclusions |
This first clinical experience with a steerable access system for EUS-BD suggests it is safe and effective, particularly with regard to controlling direction of wire advancement.
Il testo completo di questo articolo è disponibile in PDF.Abbreviations : CDS, ERC, EUS-BD, FDA, HGS, PTBD, RDV
Mappa
| DISCLOSURE: The following authors disclosed financial relationships relevant to this publication: M. Ryou: Consultant for Covidien/Medtronic, GI Windows, Pentax, Fuji, Olympus, and EnteraSense; research support from Olympus. P. C. Benias: Consultant for Covidien/Medtronic. V. Kumbhari: Consultant for Covidien/Medtronic, Pentax Medical, Boston Scientific, Apollo Endosurgery, and Obalon; research support from Apollo Endosurgery and Erbe USA. |
|
| If you would like to chat with an author of this article, you may contact Dr Kumbhari at vkumbhari@gmail.com. |
Vol 91 - N° 1
P. 178-184 - gennaio 2020 Ritorno al numeroBenvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?
